Evidence map›Paper›PMID 42794777›Full record

ReviewInternational journal of molecular sciences2026

Deubiquitinases as Regulators and Therapeutic Targets in Vascular Diseases.

Zi-Kun Lin, Lei Wang

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zi-Kun LinDepartment of Nutrition and Food Hygiene, Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing 100069, China.ORCID 0009-0001-5129-6943
Lei WangDepartment of Nutrition and Food Hygiene, Beijing Key Laboratory of Environment and Aging, School of Public Health, Capital Medical University, Beijing 100069, China.ORCID 0009-0005-0050-0691

Funding

National Center for Chronic and Noncommunicable Disease Control and Prevention 2024ZD0531200National Natural Science Foundation of China 82370263
6 · The paper itself

Abstract

Ubiquitination and deubiquitination are dynamic post-translational regulatory processes that control protein stability and signaling. Deubiquitinases (DUBs), which remove ubiquitin chains from target proteins, have emerged as important regulators of vascular homeostasis and disease. In this review, we summarize recent progress in defining the roles of DUBs in major vascular pathologies, including vascular inflammation, remodeling, neointimal formation, angiogenesis, endothelial barrier dysfunction, thrombosis, and fibrosis. Accumulating evidence indicates that distinct DUBs act in a cell type- and context-dependent manner in endothelial cells, vascular smooth muscle cells, immune cells, and fibroblasts, contributing to vascular diseases such as aortic aneurysm, atherosclerosis, pulmonary hypertension, ischemic stroke, and intimal hyperplasia. These findings support DUBs as key regulatory nodes integrating ubiquitin signaling with inflammatory and stress-response pathways in the vasculature. In parallel, efforts to pharmacologically modulate DUB activity have led to the development of selective inhibitors and activators, although challenges remain in achieving substrate specificity and tissue selectivity. Overall, DUBs represent promising therapeutic targets for vascular disease, and future studies should focus on defining disease-specific DUB-substrate networks and developing context-dependent strategies for precise vascular intervention.

Indexed as

Deubiquitinating EnzymesVascular DiseasesAnimalsHumansMolecular Targeted TherapySignal TransductionUbiquitinationDeubiquitinating Enzymesangiogenesisdeubiquitinases (DUBs)therapeutic targetsvascular diseasesvascular inflammationvascular remodeling

Identifiers

PMID42794777
PMCPMC13607605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.